Short Adult Stature Predicts Impaired β-Cell Function, Insulin Resistance, Glycemia, and Type 2 Diabetes in Finnish Men
Short Adult Stature Predicts Impaired β-Cell Function, Insulin Resistance, Glycemia, and Type 2 Diabetes in Finnish Men
复制标题
DOI：
10.1210/jc.2016-2933
复制
发表时间：
2017-02-01
影响因子：
5.8
通讯作者：
Laakso, Markku
中科院分区：
文献类型：
--
作者：
Vangipurapu, Jagadish;Stancakova, Alena;Laakso, Markku
内容：最近的研究强调了身高在复杂疾病中的作用，但关于身高作为胰岛素敏感性和2型糖尿病风险变化的预测因子的报道相互矛盾。目的：我们的目的是在一项大型前瞻性人群研究中调查身高与胰岛素敏感性、胰岛素分泌、胰岛素抵抗、2型糖尿病和心血管疾病（CVD）的关系。设计：该研究包括8746名芬兰男性（平均值+/-标准差，年龄57.2 +/- 7.1岁，体重指数26.8 +/- 3.8 kg/m2），选自基于人群的男性代谢综合征（METSIM）研究。设定：这项研究是在库奥皮奥大学医院和东芬兰大学进行的。参与者：参与者在招募时是非糖尿病患者，5401名受试者参加了随访研究。在随访期间，共有693名受试者转变为2型糖尿病，351名受试者在随访期间被诊断为新的CVD事件。主要结果指标：主要结果指标是2型糖尿病和CVD的发病率。基线测量的身高与口服葡萄糖耐量试验中2小时葡萄糖水平较低、胰岛素分泌增加、2型糖尿病风险降低[风险比（HR）= 0.83（置信区间[CI] 0.77至0.90）]和CVD [HR = 0.75（CI 0.67 ~ 0.83）]。结论：身材矮小与葡萄糖代谢的不利变化相关，并预示着2型糖尿病和心血管事件风险的增加。
Context: Recent studies have highlighted the role of height in complex diseases, but conflicting information has been reported on height as a predictor of changes in glycemia and risk of type 2 diabetes.Objective: Our aim was to investigate the association of height with insulin sensitivity, insulin secretion, glycemia, type 2 diabetes, and cardiovascular disease (CVD) in a large prospective population-based study.Design: The study included 8746 Finnish men (mean +/- standard deviation, age 57.2 +/- 7.1 years, body mass index, 26.8 +/- 3.8 kg/m(2)) selected from a population-based Metabolic Syndrome in Men (METSIM) study. Setting: The study was conducted at Kuopio University Hospital and University of Eastern Finland.Participants: The participants were nondiabetic at the recruitment, and 5401 subjects have participated in the follow-up study. During the follow-up, a total of 693 subjects converted to type 2 diabetes and 351 were diagnosed with a new CVD event during the follow-up.Main Outcome Measures: The main outcome measures were incidence of type 2 diabetes and CVD.Results: Height measured at baseline was significantly associated with lower levels of 2-hour glucose in an oral glucose tolerance test, an increase in insulin secretion, a decrease in the risk of type 2 diabetes [hazard ratio (HR) = 0.83(confidence interval [CI] 0.77 to 0.90)] and CVD [HR = 0.75(CI 0.67 to 0.83)] during the follow-up.Conclusion: Short stature is associated with unfavorable changes in glucose metabolism and predicts an increase in the risk of type 2 diabetes and cardiovascular events.